Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer

Edmond M. Kwan, Heidi Fettke, Maria M. Docanto, Sarah Q. To, Patricia Bukczynska, Andrew Mant, David Pook, Nicole Ng, Lisa Jane K. Graham, Stefano Mangiola, Eva Segelov, Kate Mahon, Ian D. Davis, Phillip Parente, Carmel Pezaro, Tilman Todenhöfer, Lisa G. Horvath, Arun A. Azad

Research output: Contribution to journalArticleResearchpeer-review

Abstract

We demonstrated that a whole-blood androgen receptor-based multigene signature was an important prognostic tool in a cohort of metastatic castration-resistant prostate cancer (mCRPC)patients receiving contemporaneous systemic treatment. This signature may have a valuable role in upfront risk stratification and prognostication of mCRPC patients.

Original languageEnglish
Number of pages8
JournalEuropean Urology Focus
DOIs
Publication statusAccepted/In press - 15 May 2019

Keywords

  • Androgen receptor
  • Androgen receptor splice variant
  • Biomarker
  • Castration-resistant prostate cancer
  • Chemotherapy
  • Prognosis

Cite this

Kwan, Edmond M. ; Fettke, Heidi ; Docanto, Maria M. ; To, Sarah Q. ; Bukczynska, Patricia ; Mant, Andrew ; Pook, David ; Ng, Nicole ; Graham, Lisa Jane K. ; Mangiola, Stefano ; Segelov, Eva ; Mahon, Kate ; Davis, Ian D. ; Parente, Phillip ; Pezaro, Carmel ; Todenhöfer, Tilman ; Horvath, Lisa G. ; Azad, Arun A. / Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer. In: European Urology Focus. 2019.
@article{56d2ba2ee82748e98f82034a29d13a65,
title = "Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer",
abstract = "We demonstrated that a whole-blood androgen receptor-based multigene signature was an important prognostic tool in a cohort of metastatic castration-resistant prostate cancer (mCRPC)patients receiving contemporaneous systemic treatment. This signature may have a valuable role in upfront risk stratification and prognostication of mCRPC patients.",
keywords = "Androgen receptor, Androgen receptor splice variant, Biomarker, Castration-resistant prostate cancer, Chemotherapy, Prognosis",
author = "Kwan, {Edmond M.} and Heidi Fettke and Docanto, {Maria M.} and To, {Sarah Q.} and Patricia Bukczynska and Andrew Mant and David Pook and Nicole Ng and Graham, {Lisa Jane K.} and Stefano Mangiola and Eva Segelov and Kate Mahon and Davis, {Ian D.} and Phillip Parente and Carmel Pezaro and Tilman Todenh{\"o}fer and Horvath, {Lisa G.} and Azad, {Arun A.}",
year = "2019",
month = "5",
day = "15",
doi = "10.1016/j.euf.2019.04.020",
language = "English",
journal = "European Urology Focus",
issn = "2405-4569",
publisher = "European Association of Urology",

}

Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer. / Kwan, Edmond M.; Fettke, Heidi; Docanto, Maria M.; To, Sarah Q.; Bukczynska, Patricia; Mant, Andrew; Pook, David; Ng, Nicole; Graham, Lisa Jane K.; Mangiola, Stefano; Segelov, Eva; Mahon, Kate; Davis, Ian D.; Parente, Phillip; Pezaro, Carmel; Todenhöfer, Tilman; Horvath, Lisa G.; Azad, Arun A.

In: European Urology Focus, 15.05.2019.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer

AU - Kwan, Edmond M.

AU - Fettke, Heidi

AU - Docanto, Maria M.

AU - To, Sarah Q.

AU - Bukczynska, Patricia

AU - Mant, Andrew

AU - Pook, David

AU - Ng, Nicole

AU - Graham, Lisa Jane K.

AU - Mangiola, Stefano

AU - Segelov, Eva

AU - Mahon, Kate

AU - Davis, Ian D.

AU - Parente, Phillip

AU - Pezaro, Carmel

AU - Todenhöfer, Tilman

AU - Horvath, Lisa G.

AU - Azad, Arun A.

PY - 2019/5/15

Y1 - 2019/5/15

N2 - We demonstrated that a whole-blood androgen receptor-based multigene signature was an important prognostic tool in a cohort of metastatic castration-resistant prostate cancer (mCRPC)patients receiving contemporaneous systemic treatment. This signature may have a valuable role in upfront risk stratification and prognostication of mCRPC patients.

AB - We demonstrated that a whole-blood androgen receptor-based multigene signature was an important prognostic tool in a cohort of metastatic castration-resistant prostate cancer (mCRPC)patients receiving contemporaneous systemic treatment. This signature may have a valuable role in upfront risk stratification and prognostication of mCRPC patients.

KW - Androgen receptor

KW - Androgen receptor splice variant

KW - Biomarker

KW - Castration-resistant prostate cancer

KW - Chemotherapy

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85065535187&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2019.04.020

DO - 10.1016/j.euf.2019.04.020

M3 - Article

JO - European Urology Focus

JF - European Urology Focus

SN - 2405-4569

ER -